Renaissance Technologies LLC Raises Stock Holdings in GSK plc (NYSE:GSK)

Renaissance Technologies LLC boosted its holdings in GSK plc (NYSE:GSK - Free Report) by 18.0% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,755,193 shares of the pharmaceutical company's stock after buying an additional 419,700 shares during the period. Renaissance Technologies LLC owned approximately 0.13% of GSK worth $93,181,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also bought and sold shares of the company. FMR LLC raised its stake in shares of GSK by 82.1% during the 4th quarter. FMR LLC now owns 52,823,032 shares of the pharmaceutical company's stock valued at $1,786,475,000 after purchasing an additional 23,814,104 shares during the period. Primecap Management Co. CA grew its holdings in GSK by 70.1% during the 4th quarter. Primecap Management Co. CA now owns 25,261,660 shares of the pharmaceutical company's stock valued at $854,349,000 after buying an additional 10,407,905 shares in the last quarter. Fisher Asset Management LLC increased its position in shares of GSK by 1.4% during the fourth quarter. Fisher Asset Management LLC now owns 18,836,797 shares of the pharmaceutical company's stock valued at $637,061,000 after buying an additional 259,867 shares during the period. Mondrian Investment Partners LTD lifted its holdings in shares of GSK by 17.6% in the fourth quarter. Mondrian Investment Partners LTD now owns 5,838,384 shares of the pharmaceutical company's stock worth $205,920,000 after buying an additional 874,004 shares in the last quarter. Finally, Grantham Mayo Van Otterloo & Co. LLC boosted its position in shares of GSK by 12.0% in the fourth quarter. Grantham Mayo Van Otterloo & Co. LLC now owns 4,153,616 shares of the pharmaceutical company's stock valued at $140,475,000 after acquiring an additional 446,568 shares during the period. Institutional investors own 15.74% of the company's stock.

Remove Ads

Analysts Set New Price Targets

GSK has been the topic of several research analyst reports. StockNews.com raised shares of GSK from a "buy" rating to a "strong-buy" rating in a report on Friday, February 7th. Morgan Stanley began coverage on GSK in a report on Wednesday, February 12th. They issued an "equal weight" rating on the stock. Seven analysts have rated the stock with a hold rating and four have given a strong buy rating to the company's stock. According to MarketBeat, GSK has a consensus rating of "Moderate Buy" and a consensus target price of $43.25.

GSK Price Performance

GSK traded up $0.37 during midday trading on Monday, hitting $35.01. The stock had a trading volume of 2,094,172 shares, compared to its average volume of 5,253,722. GSK plc has a 1 year low of $31.72 and a 1 year high of $45.92. The company has a debt-to-equity ratio of 1.12, a quick ratio of 0.52 and a current ratio of 0.78. The business has a fifty day moving average of $37.52 and a 200 day moving average of $36.22. The company has a market cap of $72.23 billion, a P/E ratio of 22.02, a price-to-earnings-growth ratio of 1.12 and a beta of 0.56.

GSK (NYSE:GSK - Get Free Report) last announced its quarterly earnings data on Wednesday, February 5th. The pharmaceutical company reported $0.59 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.44 by $0.15. GSK had a net margin of 8.13% and a return on equity of 48.59%. As a group, equities analysts forecast that GSK plc will post 4.14 earnings per share for the current fiscal year.

GSK Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, April 10th. Stockholders of record on Friday, February 21st were issued a $0.3932 dividend. The ex-dividend date was Friday, February 21st. This represents a $1.57 annualized dividend and a dividend yield of 4.49%. This is an increase from GSK's previous quarterly dividend of $0.39. GSK's payout ratio is currently 100.63%.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.